3 Abbreviations used in this paper: PKA, protein kinase A; LTR, long terminal repeat; CRE, cAMP-responsive element; b-ZIP, basic leucine zipper; ATF, activation transcription factor; C/EBP, CCAAT/enhancer binding protein; NRE, negative regulatory element; LIP, liver-enriched transcriptional inhibitory protein; TRE, 12-O-tetradecanolyphorbol-13-acetate/phorbol ester responsive element.
S everal signal transduction pathways have been shown to regulate the expression of target genes by inducing the phosphorylation of specific transcription factors (1) . The second messenger cAMP mediates the transcriptional induction of numerous genes through protein kinase A (PKA) 3 -dependent phosphorylation of the CREB at Ser 133 (2) . CREB is a stimulusinduced 43-kDa basic leucine zipper (b-ZIP) transcription factor that binds to an octanucleotide cAMP-responsive element (CRE) (i.e., TGANNTCA) both as a homodimer and as a heterodimer in conjunction with other members of the activation transcription factor (ATF)/CREB superfamily of transcription factors (3) (4) (5) . It is now believed that the transcriptional regulation of genes containing either CCAAT/enhancer binding protein (C/EBP) or ATF/ CREB recognition sites may involve the heterodimerization between different members of the b-ZIP family. This is clearly illustrated by the recent demonstration that transcription of HIV-1 in monocytic cells is regulated by a synergistic interaction between ATF/CREB and C/EBP protein families (6) . The C/EBP-related family of nuclear transcription factors constitutes a class of proteins characterized by their ability to bind the CCAAT consensus sequence, inducing either transcriptional activation or repression of target genes (7) (8) (9) (10) . Members of this family include C/EBP␣, C/EBP␤ (also termed LAP, NF-IL6␣, IL-6DBP, AGP/EBP), C/EBP␥ (previously defined as Ig/EBP-1), C/EBP␦ (NF-IL6␤), and C/EBP⑀ (11) . Interestingly, the regulatory sequences of HIV-1, which are located within the long terminal repeat (LTR), harbor three C/EBP sites that bind C/EBP␤ (12) , and these sites are essential to initiate virus replication in cells of the monocyte/macrophage lineage (13) and in endothelial cells as recently described (14) . PKA and transcription factors of the ATF/CREB family may be critical for HIV-1 expression and regulation. In this regard, HIV-1 infection has been associated with sustained elevation of cAMP in T cell lines and in normal peripheral blood mononuclear lymphocytes (15) . Moreover, HIV-1 replication has been shown to be modulated by intracellular levels of cAMP (16, 17) . For example, activation of the cAMP/PKA pathway by cholera toxin enhances HIV-1 transcription in latently infected monocytoid U1 cells (18) . It is still unknown whether the HIV-1 genome, especially the LTR, possesses CRE sequences. However, the downstream sequence elements located in the U5 domain of HIV-1 LTR has been proposed to act as 12-O-tetradecanoylphorbol-13-acetate/phorbol ester responsive element (TRE)-like CRE that bind both AP-1 and CREB/ATF, allowing the induction of HIV-1 LTR activity through both protein kinase C and PKA activation signals (19) .
The clinical progression of diseases resulting from HIV-1 infection is controlled to a large extent by cellular processes that govern the transcriptional modulation of virus gene expression. A vast array of host-and virus-derived factors interacts with the HIV-1 LTR to influence transcriptional activity through a complex interplay between both positive and negative elements (20, 21) . It has been postulated that such cofactors may be important in disease progression by enhancing cell-to-cell transmission or through up-regulation of HIV-1 expression in latently infected cell (22) . In persons dually infected with HIV-1 and other pathogens, the inability of the host to develop an effective immune response may involve the participation of the immunosuppressive molecule PGE 2 , an oxygenated polyunsaturated fatty acid that contains a cyclopentane ring structure. PGE 2 has been shown to modulate the immune response both in vitro and in vivo (23, 24) . This hormonelike molecule has been implicated in decreasing T cell proliferation, IL-2 production, and IL-2R expression (24 -29) . PGE 2 shifts the balance of the cellular immune response away from Th1, favoring a Th2 response which drives humoral responses toward the production of IgE (30) . However, more recent findings have depicted PGE 2 as a pleiotropic molecule that can act either negatively or positively on the immune system (29) . Depending on the cell type, binding of PGE 2 to one of its six described receptors (EP 1 , EP 2 , EP 3I , EP 3II , EP 3III , and EP 4 ) can lead to phospholipase C activation, phosphatidylinositol turnover increase, activation of adenylate cyclase via cholera toxin-sensitive G ␣S proteins and mobilization of intracellular Ca 2ϩ concentration (31) . PGE 2 overproduction has been reported in HIV-1-infected individuals (32) (33) (34) (35) , and it may contribute to the immunosuppressive state observed in such individuals (36) . We have previously shown that interaction of PGE 2 with EP 4 receptor subtype in human T cells can up-regulate HIV-1 replication via both NF-B-dependent and -independent signal transduction pathways (16) . More recently, we observed that the PGE 2 -mediated induction of HIV-1 LTR activity was resulting from synergistic interactions between two specific intracellular second messengers, i.e., calcium and CREB (our unpublished observations).
In this study, we have addressed the functional role played by C/EBP family proteins and C/EBP binding sites in regulating HIV-1 LTR transcription in human T cells following PGE 2 -dependent cAMP stimulation. Through transient transfection experiments with wild-type and mutated versions of HIV-1 LTR-driven luciferase constructs, we demonstrate the importance of the two most proximal C/EBP binding sites in the PGE 2 -mediated induction of virus transcription. Results from EMSAs revealed that C/EBP proteins were translocated through the nucleus following treatment of human T cells with physiological concentrations of PGE 2 . Our results also suggest that PGE 2 -induced increase in cAMP level results in the formation of heterodimeric complexes composed of C/EBP␤ and CREB, which interact with the two most proximal C/EBP binding sites located within the HIV-1 LTR region.
Materials and Methods
Reagents PGE 2 , PMA, and PHA were purchased from Sigma-Aldrich (St. Louis, MO), while TNF-␣ was from R&D Systems (Minneapolis, MN). Forskolin was obtained from BioMol (Plymouth Meeting, PA). A stock solution of PGE 2 (1 mM) was prepared by dissolving the lyophilized product into absolute ethanol and was stored at Ϫ20°C until needed.
Cells and culture conditions
The parental lymphoid T cell line, Jurkat E6.1, was obtained from the American Type Culture Collection (Manassas, VA). The cells were grown in RPMI 1640 medium supplemented with 10% heat-inactivated FBS (Hy-Clone Laboratories, Logan, UT), 2 mM glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, and 0.22% NaHCO 3 , and were maintained at 37°C in a 5% CO 2 humidified atmosphere.
Plasmids
In our studies, we have used the constructs pLTR-LUC, pmBLTR-LUC, p Ϫ 205⌬LTR-LUC, pmC2LTR-LUC, pmC3LTR-LUC, and pmC2,3LTR-LUC, which have been kindly provided by Dr. K. Calame (Columbia University, New York, NY). pLTR-LUC and pmBLTR-LUC contain the luciferase reporter gene under the control of wild-type (GGGACTTTCC) or NF-B-mutated (CTCACTTTCC) HIV-1 HXB2 LTR (Ϫ453 to ϩ80) (13) . p Ϫ 205⌬LTR-LUC is a truncated version of pLTR-LUC lacking the negative regulatory element (NRE) of HIV-1. In pmC2LTR-LUC, pmC3LTR-LUC, and pmC2,3LTR-LUC vectors, the C/EBP binding sites of HIV-1 LTR (C2 (Ϫ178 to Ϫ159 bp) and C3 (Ϫ120 to Ϫ109)) contain site-directed mutations generated by PCR to either each or both sites (13) . pCMV-IB␣ S32A/36A expresses a dominant negative form of NF-B under the control of the CMV promoter (37) . We have also used the commercially available pCRE-LUC vector, which contains five tandem repeats of the CRE sequence and a TATA box placed upstream of the luciferase reporter gene (Stratagene, La Jolla, CA). The KCREB construct consists of a CREB cDNA with a single amino acid mutation in the DNA-binding domain, cloned into a mammalian expression vector driven by the Rous sarcoma virus promoter. This plasmid was kindly provided by Dr. R. H. Goodman (Vollum Institute for Advanced Biochemical Research, Portland, OR). The pCMV-LIP (liver-enriched transcriptional inhibitory protein), a generous gift from Dr. K. Calame, encodes for a truncated C/EBP protein that has only the DNA-binding and leucin zipper domains and possess a dominant negative role in transcriptional regulation of gene expression (38) .
Transient transfection by DEAE-dextran
Jurkat E6.1 cells (5 ϫ 10 6 ) were first washed once in a TS buffer (25 mM Tris-HCl (pH 7.4), 5 mM KCl, 0.6 mM NaHPO 4 , 0.5 mM MgCl 2 , and 0.7 mM CaCl 2 ) and resuspended in 0.5 ml of TS containing 5-40 g of the indicated plasmids and 500 g/ml DEAE-dextran (final concentration). The cells/TS/plasmid/DEAE-dextran mix was incubated for 25 min at room temperature. Cells were then diluted at a concentration of 1 ϫ 10 6 /ml using complete culture medium supplemented with 100 M chloroquine (Sigma-Aldrich). After 45 min of incubation at 37°C, cells were centrifuged, washed once, resuspended in complete culture medium, and incubated at 37°C for 24 h. To minimize variations in plasmid transfection efficiencies, transfected cells were pooled 24 h after transfection and were next separated into various treatment groups, as follows. Transiently transfected cells were seeded at a density of 10 5 cells per well (100 l) in 96-well flat-bottom plates. Cells were either left untreated or were treated with PHA/PMA (3 g/ml and 20 ng/ml, respectively), TNF-␣ (2 ng/ml), forskolin (100 M), and PGE 2 (100 nM) in a final volume of 200 l for a period of 8 h at 37°C. All experiments were performed three times and luciferase activity was evaluated within each for four different similarly treated samples by a modified version of a previously published procedure (39) . Briefly, following the incubation period, 100 l of cell-free supernatant were withdrawn from each well and 25 l of 5ϫ cell culture lysis buffer (25 mM Tris phosphate (pH 7.8), 2 mM DTT, 1% Triton X-100, and 10% glycerol) were added before incubation at room temperature for 30 min. An aliquot of cell extract (20 l) was analyzed in 96-well plates using a microtiter plate luminometer (MLX Dynex Technologies, Chantilly, VA). Each well was injected with 100 l of luciferase assay buffer (20 mM tricine, 1. 
EMSAs
Nuclear extracts were prepared according to the microscale preparation protocol as described previously (16) . In brief, Jurkat cells (10 6 ) were either left untreated or were treated with PGE 2 (100 nM) or forskolin (100 M) for 30 min at 37°C and the protein content was determined by the commercial BCA Protein Assay Reagent (Pierce, Rockford, IL). Nuclear extracts were incubated for 30 min at room temperature in the binding buffer (100 mM HEPES (pH 7.9), 40% glycerol, 10% Ficoll, 250 mM KCl, 10 mM DTT, 5 mM EDTA, 250 mM NaCl, 2 g of poly(dI-dC), 10 g of nuclease-free BSA fraction V) containing 1 ng of 32 P-5Ј end-labeled dsDNA oligonucleotide. dsDNA (100 ng) was labeled with [␥-32 P]ATP and T4 polynucleotide kinase in a kinase buffer (New England Biolabs, Beverly, MA). This mixture was incubated for 30 min at 37°C and the reaction was stopped with 5 l of 0.2 M EDTA. The labeled oligonucleotide was extracted with phenol/chloroform and passed trough a G-50 spin column. The dsDNA oligonucleotide, which was used as a probe, contained the consensus C/EBP-binding site corresponding to the sequence 5Ј-TGCAGATTGCGCAAT-3Ј and was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The sequences of the synthetic C/EBP of HIV-1 LTR oligonucleotides (C/EBP-110 and C/EBP-170) are respectively 5Ј-CTAGCATTTCATCACGTGGCC-3Ј and 5Ј-CATCGAGCTTG CTACAAGGG-3Ј. For cold competition experiments, we used commercial consensus sequences for CREB (5Ј-AGAGATTGCCTGACGTC AGAGAGCTAG-3Ј), and NFAT (5Ј-TCGAGCCCAAAGAGGAAAATT TGTTTCATG-3Ј) (Santa Cruz Biotechnology). In supershift experiments, nuclear extracts were preincubated for 30 min on ice with 1 g of either specific anti-C/EBP␤ or anti-CREB polyclonal Abs purchased from Santa Cruz Biotechnology. DNA-C/EBP complexes were resolved from free labeled DNA by electrophoresis in native 4% (w/v) polyacrylamide gel containing 0.5ϫ Tris-borate-EDTA. The gel was subsequently dried and autoradiographed.
Preparation of protein extracts and immunoblotting
Nuclear extracts were prepared by hypotonic detergent lysis procedures as previously described (40) . Whole cell lysates were generated by extraction with radioimmune precipitation assay buffer. Cells were washed once with PBS, scraped, pelleted, and resuspended in radioimmune precipitation assay buffer (40) . Protein extracts were then incubated for 20 min on ice with periodic shaking. Cellular debris were pelleted down by centrifugation at 14,000 rpm for 5 min, and the supernatant was collected and stored at Ϫ80°C. Nuclear or whole cell extracts were mixed with an equal volume of sample buffer, heated at 100°C for 5 min, and loaded on 12% sodium dodecyl sulfate polyacrylamide gels. Proteins were transferred to Immobilon membranes (Millipore, Bedford, MA) and probed with Abs against C/EBP␤ (Santa Cruz Biotechnology). The blots were developed using the ECL detection system (Pierce). Blots were then evaluated using an alphaimager spot density calculator.
Results

Treatment of human T cells with PGE 2 leads to activation and nuclear translocation of C/EBP family of proteins
To define the capacity of PGE 2 to mediate a possible activation of C/EBP family members in human T lymphoid cells, EMSAs were performed with a C/EBP probe that bears a consensus CCAAT sequence. When this probe was incubated with nuclear extracts from Jurkat cells stimulated with PGE 2 (100 nM) for 15, 30, and 60 min, a sustained signal was detected at every time point ( Fig. 1;  compare lane 1 with lanes 2-4) . These data demonstrate a rapid accumulation of C/EBP in the nucleus of Jurkat cells as early as 15 min after PGE 2 treatment. The specificity of the signal was shown by competition experiments using a 50-fold excess of the unlabeled oligonucleotide (Fig. 1, lane 5) . A similar complex was formed when cells were treated for 15 min with forskolin (100 M), a powerful cAMP-inducing agent, and such complex was also competed away by an excess of the unlabeled C/EBP probe ( Fig. 1; compare lanes 6 and 7) . Data from this series of investigations indicate that a rise in cAMP levels mediated either by PGE 2 or forskolin treatment can lead to nuclear translocation and activation of C/EBP transcription factors in human T cells.
Role of C/EBP binding sites in PGE 2 -mediated increase in HIV-1 LTR activity
Next, we assess the importance of C/EBP binding sites located within the HIV-1 LTR in the previously reported PGE 2 -dependent enhancement of virus transcription by using HIV-1 LTR reporter constructs carrying appropriate site-directed mutations. Three putative binding sites for C/EBP proteins have been described so far in the HIV-1 LTR domain ( Fig. 2A) , one located in the NRE (C1, located between Ϫ340 and Ϫ185 relative to the transcriptional start site) and the two others placed upstream from the two NF-B binding sites (C2, from Ϫ178 to Ϫ159; C3, from Ϫ120 to Ϫ109). As depicted in Fig. 2B , deletion of the most distal C/EBP site did not diminish transcription relative to the wild-type construct in cells treated with PGE 2 . On the contrary, the p Ϫ 205⌬LTR-LUC vector, which still bears the two most proximal C/EBP binding sites, is even slightly more active than the full-length LTR in response to PGE 2 stimulation (compare 12.5-and 8.9-fold increases). Interestingly, the constructs containing mutations at either of the two most proximal C/EBP sites (i.e., pC2LTR-LUC and pC3LTR-LUC) had activities that were significantly decreased and were only minimally different from those of the construct lacking both proximal sites (i.e., pC2, 3LTR-LUC). These data suggest that the two most proximal C/EBP binding sites are functionally equivalent in the activation of HIV-1 LTR activity that is seen upon PGE 2 treatment of human T lymphoid cells. It should be mentioned that deletion of each or both of the two most proximal C/EBP binding sites had no effect on LTR activity in Jurkat cells stimulated by the proinflammatory cytokine TNF-␣ (2 ng/ml) or the combination of PHA and PMA (3 g/ml and 20 ng/ml, respectively) (data not shown).
We have previously shown that PGE 2 mediates up-regulation of HIV-1 LTR activity partly via the ubiquitous mammalian transcription factor NF-B (16) . In an attempt to define the exact contribution of C/EBP binding site(s) in the noticed effect of PGE 2 on HIV-1 LTR and to eliminate the potential interference made by NF-B, cotransfection studies were conducted with a vector coding for a dominant negative repressor of NF-B (i.e., pIB␣ S32A/36A ). As expected, the ability of PGE 2 to activate the full-length HIV-1 LTR (i.e., pLTR-LUC) was reduced by cotransfecting Jurkat cells with pIB␣ S32A/36A (compare Fig. 2, B and C) . This observation is in agreement with our previous findings that indicate that PGE 2 positively affect the regulatory sequences of HIV-1 through both NF-Bdependent and -independent signal transduction pathways (16) . Cotransfection of Jurkat cells with the construct lacking the two most proximal C/EBP binding sites and the dominant negative repressor of NF-B resulted in complete inhibition of PGE 2 -induced activation, indicating that the positive PGE 2 -dependent modulatory effect on HIV-1 LTR activity involves NF-B and transcription factor(s) that can bind to C/EBP sites.
Functional role of C/EBP proteins in the induction of HIV-1 LTR transcription by PGE 2
To further incriminate the involvement of C/EBP in PGE 2 -mediated effect on HIV-1 transcription, transient transfection experiments were conducted using the expression vector pCMV-LIP. This vector codes for a truncated form of C/EBP␤, LIP that acts as a trans-dominant negative regulator of C/EBP family activators. LIP contains the conserved basic leucine zipper domain which permits DNA binding and dimerization but lacks the strong transcriptional activation domain. Thus, inactive heterodimers are preferentially formed between LIP and C/EBP activators rather than self-heterodimers (13, 38) . Cotransfection of Jurkat cells with the full-length HIV-1 LTR along with increasing amounts of pCMV-LIP resulted in a dose-dependent decrease of PGE 2 -mediated reporter gene activity (Fig. 3A) . This inhibitory effect is cAMP dependent because the C/EBP dominant negative LIP also impairs HIV-1 LTR activity following forskolin stimulation, whereas it has no noticeable effect on PHA/PMA-induced activation.
The pmBLTR-LUC construct contains the complete HIV-1 LTR region but lacks the two B binding sites. This vector is thus ideal to identify the region(s) responsible for NF-B-independent activation of HIV-1 transcription in human T cells treated with PGE 2 . Cotransfection of pmBLTR-LUC and increasing concentrations of pCMV-LIP led to a marked decrease in both PGE 2 -and forskolin-mediated induction of LTR activity (Fig. 3B) . These results are consistent with those obtained with the full-length HIV-1 LTR (Fig. 3A) . Again, the introduction of LIP did not alter luciferase activity in cells stimulated with the combination of PHA and PMA.
PGE 2 treatment leads to the formation of heterodimeric C/EBP␤-CREB complexes
EMSAs were next performed to examine proteins in Jurkat nuclear extracts which could bind to the two most proximal C/EBP binding sites in the HIV-1 LTR domain (called C/EBP-110 and C/EBP-170 for the purpose of these experiments). First, using an oligonucleotide probe representing the C/EBP-110 site, a more intense retarded complex was observed following treatment of Jurkat cells with either PGE 2 or forskolin ( Fig. 4A ; compare lane 2 with lanes 3 (forskolin) and 4 (PGE 2 )). The formation of this complex was competed for by an excess of either the homologous (C/EBP-110) or heterologous (C/EBP-170) competitor ( Fig. 4 ; compare lane 4 with lanes 5 (C/EBP-110) and 6 (C/EBP-170)). Interestingly, this complex was also competed away by an excess of both unlabeled consensus C/EBP (Fig. 4; compare lanes 4 and 7) and CRE (Fig.  4; compare lanes 4 and 8) but not a NFAT probe (Fig. 4; compare  lanes 4 and 9) . NFAT was chosen as a negative control because previous unpublished observations suggest that NFAT is not activated upon treatment of Jurkat cells with PGE 2 . The induced complex was almost totally abrogated when a C/EBP␤ or CREB polyclonal antiserum was included in the EMSA reaction mixture ( Fig.  4 ; compare lane 4 with lanes 10 (anti-C/EBP␤) and 11 (anti-CREB)), demonstrating that both C/EBP␤ and CREB are major components of the C/EBP-110 binding site complex in Jurkat cells exposed to PGE 2 . Of interest to note was the formation of two distinct complexes (CI and CII) when using an oligonucleotide probe representing the C/EBP site which spans the Ϫ170-bp site in the HIV-1 LTR (Fig. 4B) . Moreover, the second complex (i.e., CII) is primarily affected by an excess of unlabeled probes for either C/EBP-110, C/EBP-170, consensus C/EBP, or CRE. Ab against C/EBP␤ or CREB altered the formation of the second complex without affecting the upper one, suggesting that neither CREB nor C/EBP␤ is implicated in the formation of CI. We also used the consensus sequence for C/EBP as a probe for gel shift assays, and results were consistent with those obtained with the C/EBP-110 probe, except that competition with C/EBP and CRE caused a more complete disappearance of the complex induced by PGE 2 treatment (Fig. 4C) .
To scrutinize the possible functional synergistic interaction between C/EBP and CREB within the context of the HIV-1 LTR, Jurkat cells were cotransfected with HIV-1 LTR constructs containing mutations in each of the two proximal C/EBP binding sites along with a vector coding for KCREB, a trans-dominant negative repressor of CREB. KCREB mutant contains a single base pair substitution in the DNA-binding domain (changing Arg 287 to Leu) that destroys its DNA-binding ability and allow the quenching of factor(s) capable of associating with CREB by heterodimerization (41) . Data obtained from this set of experiments demonstrate that addition of KCREB severely reduced PGE 2 -induced up-regulation of HIV-1 LTR activity (Fig. 5) . Indeed, levels of diminution of 62.2 and 58.9% were observed with mC2LTR-LUC and mC3LTR-LUC constructs, respectively. A comparable reduction in HIV-1 LTR-driven gene expression was obtained with the other intracellular cAMP-increasing agent, forskolin. These experiments were repeated several times and gave consistent results. Altogether our data show that activation of the HIV-1 promoter in human T lymphoid cells with the cAMP inducer agent PGE 2 involved the participation of both C/EBP and CREB transcription factors.
Treatment of Jurkat cells with PGE 2 results in nuclear translocation of C/EBP. In an attempt to demonstrate that PGE 2 treatment of Jurkat cells modifies the amount of C/EBP␤ in the nucleus, Western blot experiments were performed with whole cell lysates and nuclear extracts from treated cells. As shown in Fig. 6 , a transient accumulation of C/EBP␤ in the nucleus is seen over time following treatment of Jurkat cells with PGE 2 (i.e., 2-to 3.5-fold increase). This noticed change in the nuclear concentration of C/EBP␤ is not due to an increased synthesis of this protein because its concentration remained constant in whole cell extracts.
Discussion
The formation and production of elevated levels of inflammatory mediators such as PGE 2 are a hallmark of HIV-1 infection (33) (34) (35) . Prostaglandins play an important role in disease exacerbation by directly altering T cell functions or macrophage activation. Although PGE 2 was initially envisaged as an immunosuppressive molecule that acts as a down-regulator of many aspects of B and T cell function and proliferation, recent findings support a role for PGE 2 as a potentiator of Ig class switching and of cytokine and cytokine receptor synthesis (29) . Given that PGE 2 is a strong inducer of cAMP and that a 4-fold increase in intracellular levels of cAMP is seen in asymptomatic HIV-1-seropositive subjects as compared with uninfected controls (42) , we previously assessed whether PGE 2 could affect HIV-1 transcriptional activity in human T cells. Our findings demonstrate that PGE 2 can act as a potent activator of HIV-1 LTR-driven transcription through an effect on both NF-B-dependent and -independent signaling events (16) . More recently, calcium and the CREB transcription factor were also found to be essential second messengers in the PGE 2 -mediated up-regulation of LTR activity in T cells (our unpublished observation). Although the binding of a member of the CREB family to the HIV-1 LTR via the CRE consensus sequence has not yet been described, it has been postulated that CREB can act indirectly on the regulatory elements of this retrovirus. For example, it has been shown that CREB interacts with HIV-1 LTR through an association with transcription factors such as TFIID and TFIIB (43) (44) (45) or with the adapter CBP; the latter is known to interact with the general transcription machinery (46) . Recently, a recognition sequence for members of the ATF/CREB family was identified within the untranslated leader region of HIV-1 as a novel TRE-like CRE capable of binding both AP-1 and ATF/CREB (47) . However, the U5 region of the HIV-1 LTR is absent from our molecular constructs, rejecting the possible implication of TRElike CRE in the noticed PGE 2 -induced viral activation. A recent report has shown that dopamine treatment of HIV-1-infected T cells leads to the binding of CREB to the COUP-TF sequence that is located at the 5Ј end of the HIV-1 LTR in a region called the NRE (43) . The various LTR constructs used in the present study do not bear the NRE, suggesting that the COUP-TF binding domain is not participating in PGE 2 -mediated effect. In the present study, we have analyzed in more details the precise binding site(s) or binding mechanism of the transcription factor CREB on HIV-1 LTR following treatment with PGE 2 .
The recent observation that complex interactions appear to occur between ATF/CREB and C/EBP in the context of the HIV-1 LTR (6) has prompted us to assess the ability of PGE 2 to mediate C/EBP activation in human T lymphoid cells. The C/EBP family of nuclear proteins is a member of a larger superfamily of transcription factors characterized by the b-ZIP motif that also in-cludes the ATF/CREB family (48) . In a number of cell types, C/EBP␤ has been shown to function as a cAMP-activated transcription factor (49 -51) . We found that treatment of Jurkat cells with PGE 2 resulted in a noticeable induction of nuclear translocation and activation of C/EBP. Indeed, DNA mobility shift assays provided clear evidence that PGE 2 and forskolin treatment of human T cells increases the level of specific protein-DNA complexes when the consensus C/EBP binding site is used as a molecular probe (Fig. 1) . Although treatment of Jurkat cells with PGE 2 did not alter the protein level of C/EBP␤ in whole cell extracts, there was a redistribution of this protein from the cytoplasm to the nucleus upon exposure to PGE 2 (Fig. 6) .
A previous study has reported that C/EBP proteins and their binding sites are required for HIV-1 proviral induction in both promonocytic U937 cells and primary macrophages. In their experimental system, Henderson and colleagues (52, 53) have demonstrated that Jurkat and H9 T lymphoid cell lines express several C/EBP family transcriptional activators, including C/EBP␣, C/EBP␤, and C/EBP␦, which are present primarily in the nuclear fraction. However, none of these proteins was found to be induced upon activation with the diacylglycerol analog PMA or the mitogenic agent Con A (53) . We noticed that PGE 2 and forskolin, both of which are known to induce an elevation of the intracellular cAMP level, were able to potently activate C/EBP in human T cells. The functional role played by C/EBP in PGE 2 -induced activation of virus transcription was demonstrated by transient transfection experiments using vectors carrying mutations in C/EBP binding sites that are present in the HIV-1 LTR. PGE 2 -mediated increase in HIV-1 LTR-driven luciferase activity was considerably reduced when Jurkat cells were transfected with molecular constructs bearing site-directed mutations within the two most proximal C/EBP binding site(s) (Fig. 2) . C/EBP sites were not involved in the induction of LTR activity in response to PHA/PMA or TNF-␣ (data not shown). These data were expected, considering that such stimuli are unable to lead to an increase in cAMP level. The biological relevance of the HIV-1 C/EBP binding sites is provided by the observation that this sequence appears to be well conserved in primary HIV-1 isolates from AIDS patients over several years (54) .
It has been previously demonstrated that individual C/EBP proteins can homodimerize or heterodimerize with other members of the C/EBP family of b-ZIP domain proteins to elicit specific cAMP-mediated transcriptional stimulation or repression (9, 49, 55) . Moreover, it is now believed that transcriptional regulation of genes containing the recognition sites of either C/EBP or ATF/ CREB may result from heterodimeric formation between different members in each of the C/EBP and ATF/CREB families (56) . This mechanism may be used to respond to complex signals and transcriptional cues through single sequence elements including a response to cAMP, despite the absence of active CRE, AP1, and AP2 consensus nucleotide sequences (57) (58) (59) . The best example is provided by the CFTR gene promoter that is controlled by interactions between C/EBP and ATF/CREB family members with CREB1 and ATF1 binding to the inverted CCAAT element of this gene to finely regulate its transcription (59) . Although the absence of CRE certainly may not preclude ATF or CREB protein from targeting promoters devoid of such cis-acting elements, it is interesting to note that regulation of the somatostatin gene requires protein-protein interaction between C/EBP and ATF/CREB transcription factors to elicit a cAMP-dependent response through the CRE element (60) . Inversely, C/EBP proteins have been shown to bind specifically to the phosphoenolpyruvate carboxykinase gene CRE with high affinity to promote cAMP-mediated transcriptional activation (61). In addition, previous studies identified C/EBP as an effector of cAMP-mediated transcription of the phosphoenolpyruvate carboxykinase gene through combined interactions with liverspecific transcription factors (62, 63) . Experiments conducted with a vector coding for LIP suggested that C/EBP was playing a crucial role in activation of HIV-1 LTR-driven gene expression that is seen following treatment of human T cells with PGE 2 (Fig. 3 ). It should be noted that the ␤-isoform of C/EBP has been intimately linked with the cAMP signaling system, as exemplified by the reported capacity of cAMP to stimulate C/EBP␤ gene expression (61) and translocation of C/EBP␤ from the cytosol to the nucleus (49) . Thus, we propose that the PGE 2 -dependent increase in HIV-1 LTR transcriptional activity is mediated in part by C/EBP␤. Our data indicate that the dominant negative form of C/EBP, i.e., LIP, has less impact on PGE 2 -mediated induction of HIV-1 LTR-driven activity than mutating the C/EBP binding sites, suggesting that factors in addition to C/EBP may be binding to C/EBP binding sites. Experiments are presently underway to address this issue.
Results gathered from mobility shift assays suggested that PGE 2 treatment of human T cells results in nuclear translocation of C/EBP␤-CREB complexes that can bind to the two most proximal C/EBP sites located within the HIV-1 LTR (Fig. 4 ). The formation of heterodimeric complexes constituted of C/EBP␤ and CREB transcription factors in response to PGE 2 in T cells was clearly shown by cross-competition and supershift assays. The use of probes specific for the two most proximal C/EBP binding sites within the HIV-1 LTR (C/EBP-110 and -170) have confirmed the importance of both sites. Finally, the functional role played by CREB in PGE 2 -mediated activation of HIV-1 LTR was shown by using a dominant negative version of CREB ( Fig. 5 ). Our findings that part of the PGE 2 -dependent positive modulatory effect on HIV-1 LTR activity is due to heterodimeric formation between C/EBP␤ and CREB is perfectly in line with a recent study by Ross and coworkers (6) . These investigators have indeed reported that HIV-1 LTR transcription is enhanced following stimulation of U937 monocytoid cells with IL-6 due to synergistic interactions between C/EBP and CREB transcription factors.
In summary, we have more deeply investigated the regulation of HIV-1 gene transcription following PGE 2 -mediated increase in intracellular cAMP levels in human T cells. We have identified C/EBP␤ as a PGE 2 -activated transcriptional regulator of HIV-1 LTR in Jurkat cells and demonstrated that C/EBP binding sites are functionally important for virus transcription. We also suggest that functional and physical association between members of two important transcription factor families, i.e., C/EBP␤ and CREB, are required for activation of HIV-1 transcription by PGE 2 . Our findings represent a further indication of the high complexity of the molecular mechanisms that regulate HIV-1 gene expression following treatment of human T cells with PGE 2 .
